Shares of United Therapeutics Co. (NASDAQ:UTHR) have received a consensus rating of “Hold” from the fourteen ratings firms that are covering the company, MarketBeat reports. Four research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $140.27.
A number of equities analysts have issued reports on the company. ValuEngine raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 26th. Zacks Investment Research raised United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 price target for the company in a research note on Monday, January 15th. HC Wainwright reaffirmed a “hold” rating and set a $95.00 price target on shares of United Therapeutics in a research note on Thursday, October 26th. Credit Suisse Group reaffirmed an “underperform” rating and set a $118.00 price target on shares of United Therapeutics in a research note on Thursday, January 18th. Finally, BidaskClub lowered United Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 16th.
In other United Therapeutics news, Director Christopher Causey sold 580 shares of the stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $134.72, for a total transaction of $78,137.60. Following the transaction, the director now directly owns 1,555 shares of the company’s stock, valued at $209,489.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Martine A. Rothblatt sold 1,253 shares of the stock in a transaction on Friday, November 24th. The stock was sold at an average price of $124.07, for a total transaction of $155,459.71. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,136 shares of company stock valued at $1,248,989. 7.80% of the stock is owned by corporate insiders.
Shares of United Therapeutics (NASDAQ:UTHR) traded down $0.33 during mid-day trading on Tuesday, reaching $129.17. The company had a trading volume of 327,749 shares, compared to its average volume of 403,918. United Therapeutics has a 1-year low of $112.01 and a 1-year high of $169.89. The company has a market cap of $5,561.69, a price-to-earnings ratio of 11.42 and a beta of 1.26.
United Therapeutics Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.